Khaya grandifoliola C.DC: a potential source of active ingredients against hepatitis C virus in vitro

Medicinal plant molecules against hepatitis C virus: Current status and future prospect

Hepatitis C virus (HCV), a global malady, causes acute and chronic hepatitis leading to permanent liver damage, hepatocellular carcinoma, and death. Modern anti-HCV therapies are efficient, but mostly inaccessible for residents of underdeveloped regions. To innovate more effective treatments at affordable cost, medicinal plant-based products need to be explored. The aim of this article is to review plant constituents in the light of putative anti-HCV mechanisms of action, and discuss existing problems, challenges, and future directions for their potential application in therapeutic settings. One hundred sixty literatures were collected by using appropriate search strings via scientific search engines: Google Scholar, PubMed, ScienceDirect, and Scopus. Bibliography was prepared using Mendeley desktop software. We found a substantial number of plants that were reported to inhibit different stages of HCV life cycle. Traditional medicinal plants such as Phyllanthus amarus Schumach. and Thonn., Eclipta alba (L.) Hassk., and Acacia nilotica (L.) Delile exhibited strong anti-HCV activities. Again, several phytochemicals such as epigallocatechin-3-gallate, honokilol, punicalagin, and quercetin have shown broad-spectrum anti-HCV effect. We have presented promising phytochemicals like silymarin, curcumin, glycyrrhizin, and camptothecin for nanoparticle-based hepatocyte-targeted drug delivery. Nevertheless, only a few animal studies have been performed to validate the anti-HCV effect of these plant products. Again, insufficient clinical evaluation of the safety and effectiveness of herbal medications remain a problem. Selected plants products could be developed as novel therapeutics for HCV patients only after scrupulous evaluation of their safety and efficacy in a clinical set-up.

Hydro-ethanolic extract of Khaya grandifoliola attenuates heavy metals-induced hepato-renal injury in rats by reducing oxidative stress and metals-bioaccumulation

People living in developing countries are exposed to hepato-renal injuries induced by heavy metals like lead (Pb), cadmium (Cd), and mercury (Hg) since drinking water supplied is often polluted with a high concentration of those metals. Accordingly, it is necessary to search for antidotes against heavy metals poisoning. Hence, medicinal plants bearing anti-hepatotoxic properties represent a credible option; and such plant is Khaya grandifoliola. However, there is a paucity of knowledge regarding its protective effect on heavy metals-induced hepato-renal toxicity. Thus, this study was designed to assess the protective effect of the hydro-ethanolic stem bark extract of K. grandifoliola (HKG) against hepato-renal injuries induced by chronic consumption of drinking water containing high contents of Pb, Cd, and Hg; in addition to the investigation of the chemical antioxidant properties of HKG. For the antioxidant assays, HKG was tested as a potential inhibitor of lipid peroxidation, reducer of ferric and phosphomolybdenum, and scavenger of hydroxyl and 2,2-Diphenyl-Picryl-Hydrazyl radicals. Its protective effects were evaluated by daily co-treating rats with heavy metals solution (10 mL/kg b.w) containing 0.9, 0.58, and 1.13 ppm respectively for Pb, Cd and Hg and HKG (25 or 100 mg/kg b.w) for five consecutive months; and biochemical parameters associated to liver and kidneys functions, oxidative stress and metals bioaccumulation were assessed. HKG displayed a strong antioxidant capacity (IC50/EC50 range 3.95–17.17 μg/mL) correlated to its polyphenols content and comparable to that of Ascorbic acid. Serum levels of alkaline phosphatase, alanine/aspartate aminotransferase, and creatinine; renal and hepatic content of Cd and Pb, malondialdehyde and glutathione, activities of superoxide dismutase and catalase showed the protective effect of HKG, further evidenced by histopathological analysis. Taking together, these results demonstrated that HKG alleviates heavy metals-induced hepato-renal injuries in rats by reducing oxidative stress and metals-bioaccumulation.

Plants extracts from Cameroon pharmacopeia strongly inhibit the Chikungunya virus infection by targeting entry and replication steps

ETHNOPHARMACOLOGICAL RELEVANCE

Cameroon is one of the sub-Saharan African countries affected by Chikungunya virus (CHIKV). With the absence of approved treatment, this disease represents globally a major public health concern. Several plants are traditionally used in Cameroon for the treatment of virus induced fever and arthralgia. But to date there is no study that validate the efficacy of these plants for the treatment of Chikungunya virus infection.

AIM OF THE STUDY

This study aims to explore the inhition effect, mechanism of action of plant extracts against Chikungunya virus.

MATERIAL AND METHODS

An ethnobotanical survey conducted in some regions of Cameroon, led to the identification of nine medicinal plants used in traditional medicine for the healing of fever-related diseases and arthritis. Crude hydro-ethanolic extracts of each plant were prepared by maceration and their effects against CHIKV infection were investigated. CHIKV S27 strain was used to infection in Vero cell line. The antiviral activities were determined by plaque assay and/or RT-PCR targeting E1 envelope gene of CHIKV. Dose-response studies of the active plants were also determined by flow cytometry and Western blot.

RESULTS

Four extracts, Entada africana Guill et Pers. (E4), Entandrophragma cylindricum Sprague (EI), Khaya grandifoliola C. D.C. Sapindales (E2) and Macaranga hurifolia Beille (E6) showed antiviral activity with the half-maximal inhibitory concentration of 8.29; 8.14; 12.81 and 26.89 μg/mL respectively. All extracts were nontoxic up to the concentration of 100 μg/μL. Entandrophragma cylindricum Sprague (EI), Khaya grandifoliola C. D.C. Sapindales (E2), and Entada africana Guill et Pers. (E4) showed strong inhibition on the entry step of viral infection. At the same time, only Entandrophragma cylindricum Sprague (EI) inhibited the viral titer significantly in replication and intercellular assembly steps. Four plant extracts namely Entandrophragma cylindricum Sprague (EI), Macaranga hurifolia Beille (E6), Phragmentera capitata (Sprengel) Balle (E12), and Detarium microcarpum (E13) were effective against egression step.

CONCLUSIONS

Together, the results of this study showed anti-chikungunya activities of Entandrophragma cylindricum Sprague (EI) and Macaranga hurifolia Beille (E6), with therapeutics perspectives and can be promising sources of the development of anti-CHIKV molecule in future.

Khaya grandifoliola C. DC. (Meliaceae: Sapindales): Ethnobotany, phytochemistry, pharmacological properties, and toxicology

ETHNOPHARMACOLOGICAL RELEVANCE

Khaya grandifoliola is a well-known tree species in Africa with a conservation status of 'vulnerable' due to its overexploitation by the wood industry. Several studies have recorded numerous ethnobotanical uses of this plant, as well as the scientific validation of the efficacy of extracts from different plant parts used for the treatment of various ailments. However, this useful information is scattered throughout the literature and thus there is no opportunity to identify the existing knowledge gaps.

AIM OF THE STUDY

This review aims to highlight the medicinal importance of Khaya grandifoliola including its known phytochemistry, biological activities and toxicology, to encourage a refocused conservation strategy since all current efforts are geared towards maintaining its continuous supply to the wood industry.

MATERIALS AND METHODS

Articles on K. grandifoliola were sourced from online databases such as Google Scholar, Medicine, PubMed, Science Direct, Scopus, SciFinder and other science journal websites up to May 2020. The search was conducted using various combinations of keywords such as biotechnological uses, biological activity, ethnobotany, ethnomedicine, indigenous uses, pharmacological activity, phytochemistry, proximate composition, toxicity, and traditional uses of K. grandifoliola. All downloaded articles were screened to determine their relevance to the scope of the review and the selected papers were included.

RESULTS

The review revealed a host of ethnomedicinal uses such as anticancer, antidiabetic, antimicrobial, anti-sickling, anti-ulcerogenic, and hepatoprotective, many of which are supported by scientific data. More importantly, toxicity tests revealed that many of the extracts are safe at various therapeutic doses. Important knowledge gaps that should be explored include phytochemical characterization and validation of some ethnobotanical claims on the folkloric usage of the plant.

CONCLUSIONS

Notwithstanding the importance of K. grandifoliola in the wood industry, this review reveals that its use as a medicine is equally important. Its medicinal uses are also well supported with scientific studies as well as favourable toxicological studies though some scientific knowledge gaps require further studies.

Biological activities of limonoids in the Genus Khaya (Meliaceae): a review

Background

Limonoids are a class of highly oxygenated modified triterpenoids with a diverse range of biological activities. Although with restricted occurrence in the plant kingdom, these compounds are found extensively in the Meliaceae and Rutaceae families. Limonoids are of great interest in science given that the small number of plant families where they occur exhibit a broad range of medicinal properties that promote health and prevent disease.

Main text

The Meliaceae family includes the genus Khaya and comprises tree species that have been used in traditional medicine to treat several ailments. In recent years, the genus Khaya has attracted much research interest owing to the presence of limonoids in different plant parts of a few species that can serve as therapeutic molecules in the pharmaceutical industry. In this study, a literature search over the past two decades (2000–2020) was conducted on the biological activities of limonoids in the genus Khaya using different databases such as Google Scholar, PubMed, Scopus and ISI Web of Science. The taxonomy, geographical distribution and the various traditional uses of the genus are presented in detail. This study reveals that the currently documented biological activities of limonoids both in vivo and in vitro are limited to four species (K. anthotheca, K. grandifoliola, K. ivorensis and K. senegalensis) in the genus Khaya, and include anticancer, antimalarial, hepatoprotection, anti-inflammatory, neuroprotection, antimicrobial, antifungal and antifeedant. The most well-researched species, K. senegalensis, has the most notable biological activities and traditional uses in the genus Khaya.

Conclusion

The present detailed and up-to-date review of recent literature on the biological activities in the genus Khaya reveals the potentials of limonoids for drug development in managing several ailments.

Natural products for the management of the hepatitis C virus: a biochemical review

Chronic hepatitis C virus (HCV) infection is a significant public health problem, with a worldwide prevalence of approximately 170 million. Current therapy for HCV infection includes the prolonged administration of a combination of ribavirin and PEGylated interferon-α, for over a decade. This regimen is expensive and often associated with a poor antiviral response and unwanted side effects. A highly effective combination treatment is likely required for the future management of HCV infections and entry inhibitors could play an important role. Currently, no entry inhibitor has been licensed for the prophylactic treatment of hepatitis C. Therefore, additional agents that combat HCV infection are urgently needed and must be developed. Many phytochemical constituents have been identified that display considerable inhibition of HCV at some stage of the life cycle. This review will summarise the current state of knowledge on natural products and their possible activities in the context of HCV infection.

Hepatitis C in Cameroon: What is the progress from 2001 to 2016?

Chronic hepatitis C is a major public health problem in sub-Saharan countries and particularly in Cameroon where the prevalence rate is around 7.6% in the age group of 55-59 years. Recent investigations into this infection allowed defining a national seroprevalence, characterizing virological and biological profiles of infected patients and identifying medicinal plants of potential interest in hepatitis C therapy. However, in Cameroon, no existing report currently presents a good overview of hepatitis C research in relation to these parameters. This review seeks to discuss major findings published since 2001 that have significantly advanced our understanding of the epidemiology and treatment of hepatitis C in Cameroonian patients and highlight the major challenges that remain to overcome. We performed a systematic search in Pubmed and Google Scholar. Studies evaluating prevalence, treatment, coinfection, and genetic diversity of HCV infection in Cameroon were included. Studies suggest that HCV prevalence in Cameroon would be low (around 1.1%) with a lot of disparities according to regions and age of participants. Elders, pregnant women, blood donors, health care workers, patients on hemodialysis, and homozygous sickle cell patients have been identified as risk groups. Moreover, HCV/HBV coinfection was found more prevalent than HCV/HIV coinfection. Phylogenic studies reported circulation of three main genotypes such genotypes 1, 2, and 4 but little is known about antiviral candidates from the Cameroonian pharmacopeia. In conclusion, some epidemiological data prove that hepatitis C in Cameroon is well known but efforts are still necessary to prevent or control this infection.